Eyenovia (NASDAQ:EYEN) Announces Earnings Results, Beats Estimates By $5.61 EPS

Eyenovia (NASDAQ:EYEN) issued its earnings results on Monday. The company reported ($1.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($7.20) by $5.61, Zacks reports. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. The business had revenue of $1.60 million during the quarter, compared to analyst estimates of $1.60 million.

Eyenovia Stock Performance

Eyenovia stock traded up $0.54 during mid-day trading on Tuesday, hitting $1.67. The company had a trading volume of 49,461,403 shares, compared to its average volume of 828,014. The company has a market capitalization of $4.73 million, a price-to-earnings ratio of -0.03 and a beta of 0.76. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.58. The company’s fifty day moving average is $1.17 and its 200-day moving average is $5.96. Eyenovia has a 12-month low of $0.85 and a 12-month high of $124.80.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 price target on shares of Eyenovia in a report on Friday, March 21st.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.